See the DrugPatentWatch profile for Izervay
The generic name for Izervay is izokibep [1].
What is Izervay used for?
Izervay is a medication being developed for the treatment of cystic fibrosis [2]. It is designed to target specific inflammatory pathways involved in the disease [2].
When will Izervay be available?
The availability of Izervay depends on the completion of clinical trials and regulatory approval. Data from Phase 2b trials are expected, and the drug's progression towards market release is contingent on these results [2].
What are the competitors to Izervay?
Other treatments for cystic fibrosis exist, including existing modulator therapies that target the underlying genetic defect in cystic fibrosis. Izokibep's development positions it as a potential new option, particularly for addressing inflammatory aspects of the disease [2].
Are there any clinical trials for Izervay?
Yes, Izervay has been studied in clinical trials. Phase 2b studies are ongoing and are expected to provide further data on its efficacy and safety [2].
What are the potential side effects of Izervay?
Specific side effects for Izervay are typically detailed as clinical trials progress and are made public through regulatory submissions. Information on adverse events from ongoing studies will become available as data matures [2].
Who is developing Izervay?
Izervay is being developed by Spherix [2].
How does Izervay work?
Izervay is an interleukin-17 (IL-17) inhibitor. IL-17 is a pro-inflammatory cytokine that plays a role in the inflammation seen in cystic fibrosis patients. By inhibiting IL-17, Izervay aims to reduce lung inflammation [2].
---
Sources:
1. DrugPatentWatch.com
2. Spherix (Accessed October 26, 2023)